Outside of clinical trials, experience with daratumumab-based combination therapies (DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and dexamethasone (d) in relapsed/refractory multiple myeloma (RRMM) is limited. We reviewed the outcomes of 126 patients who received 1 cycle of any DCT. Median age at DCT initiation was 67 (range, 43-93) years. Highrisk cytogenetics was present in 33% patients. Median number of prior therapies was 4 (range, 1-14) and time to first DCT from diagnosis was 4.3 years (range, 0.4-13.0). Seventeen (13%) patients were refractory to single agent daratumumab. Fifty-two (41%), 34 (27%), 23 (18%), and 17 (14%) received DPd, DRd, DVd and "other" DCTs, respectively. Overall response rate was 47%. Median follow-up was 5.5 months (95% CI, 4.2-6.1). Median progression-free survival (PFS) was 5.5 months (95% CI, 4.2-7.8). Median overall survival was not reached (NR) with any regimen. Median PFS (months) was worst for penta-refractory MM (n 5 8) vs quadruple refractory MM (n 5 18) and others (n 5 100) (2. 
had received at least 3 prior therapies and were exposed to an alkylating agent had a median overall survival (OS) of only 13 months and progression-free survival (PFS) of 5 months. 6 Daratumumab is a first-in-class, human IgG-j monoclonal antibody against the CD38 antigen expressed on malignant PCs. Daratumumab induces death of PCs by cell-mediated cytotoxicity, antibody dependent phagocytosis and apoptosis. Besides, daratumumab acts as an immunomodulator by depleting CD381 immunosuppressive lymphoid and myeloid cells and inducing an increase in the activity of cytotoxic T-lymphocytes. [7] [8] [9] Daratumumab showed safety and efficacy in RRMM as a single agent, and in combination in multiple trials. [10] [11] [12] [13] Daratumumab was efficacious with no significant added toxicity in combination with backbone regimens including bortezomib, thalidomide and dexamethasone (VTD), bortezomib, melphalan and prednisolone (VMP), and pomalidomide and dexamethasone. 14 Phase 3 trials comparing the use of daratumumab with bortezomib or lenalidomide, and dexamethasone (CASTOR and POLLUX, respectively) against the "standard-ofcare" regimens showed exceptional results with daratumumab-based combination therapies (DCTs), characterized by deep responses and longer PFS. [15] [16] [17] [18] Daratumumab was approved in the US for use as monotherapy in patients who received at least 3 prior lines of therapy, including a PI and an IMiD or who were refractory to a PI and an IMiD in November 2015. Subsequently, in 2016, based on the findings of CASTOR and POLLUX studies, it was approved in combination with bortezomib or lenalidomide plus dexamethasone, for those who received at least 1 prior therapy. 15, 16, 19 In 2017, daratumumab with pomalidomide and dexamethasone (DPd) was approved for use in patients who received 2 prior therapies based on the results of EQUULEUS trial. 20 In a previous report examining use of DPd in a small cohort of heavily pretreated patients (n 5 39), the regimen showed an overall response rate (ORR) of 41%. 21 In a similar study of 41 patients receiving DPd, ORR was 89% in patients who were daratumumab-and pomalidomide-naïve, and 41% in patients refractory to daratumumab or pomalidomide. 22 Outside of clinical trials, data on experience with DCTs are limited. In this context, we aimed to review our institutional experience with the use of DCTs in RRMM.
| M E TH ODS

| Patients
We reviewed the medical records at Mayo Clinic, Rochester, Minnesota to identify patients with RRMM who received their first DCT between 1st December 2015 and 31st December 2016. All patients had a diagnosis of MM established as per the International Myeloma
Working Group (IMWG) criteria prior to commencement of therapy. [23] [24] [25] We collected details regarding prior treatments, disease characteristics, adverse events, response to DCT, timing of disease pro- 
| Response and outcomes
Response to DCT was defined according to the 2016 IMWG criteria and included evaluation for minimal response (MR). ORR was defined as the proportion of patients attaining a partial response (PR) or better as the best response. Clinical benefit rate (CBR) was defined as the proportion of patients attaining MR or better as the best response. PFS, time-to-next treatment (TTNT), time-to-best response and duration of response (DOR) were defined as per guidelines. 26 The adverse events were graded using National Cancer Institute Common Toxicity Criteria for Adverse Events v4.0.
| Statistical analysis
Continuous variables were summarized as medians, and compared between groups using Kruskal Wallis test. Categorical variables were summarized as proportions and compared between groups using Fisher's exact test. The time-to-event analyses were performed using the Kaplan Meier method and compared between groups using log-rank test. A P-value less than .05 was considered significant for all statistical tests. We used JMP Pro 12.0 (SAS Institute Inc., Cary, NC, USA) for statistical analyses. The cause of death was progressive disease in all, except one patient who died due to pneumonia (not associated with neutropenia).
| R E SU LTS
| Treatment
In the cohort receiving DPd, patients started pomalidomide at a median patients had discontinued DCT; 49 patients due to progressive disease and 2 patients were refractory to DCT. Three patients stopped DCT and proceeded to an autologous stem cell transplant, and 1 patient switched therapy because of personal preference. One patient died while on therapy due to pneumonia.
| Response to DCT
The response to treatment was evaluable in 122 (97%) patients. ORR for the entire cohort was 47%; 20% patients attained VGPR or better, and CBR was 66%. ORR in the DPd, DRd, DVd and other DCT groups was 46%, 50%, 57%, and 35%, respectively. We observed that 16%, 29%, 14%, and 18% patients, respectively in the DPd, DRd, DVd and other DCT groups attained at least a VGPR as their best response;
CBR was 64%, 68%, 67%, and 65% in the respective groups. The Table 2 .
The ORR and CBR in patients refractory to P (n 5 22) in the DPd group were 32% and 59%, and 57% and 68% in those not refractory to P (n 5 28) (P 5 .09 and P 5 .56, respectively). ORR and CBR in patients refractory to R (n 5 25) among those who received DRd were 44% and 64% compared to 67% and 78% in those who were not refractory to R (n 5 9) (P 5 .44 and P 5 .68, respectively). ORR and CBR in patients who were refractory to V (n 5 17) among those who received DVd were 58% and 71% compared to 50% and 50% in those who were not refractory to V (n 5 4) (P 5 1.0 and P 5 .57, respectively). Among patients who received DPd and were not refractory to P, 7 (25%) were refractory to daratumumab; while among those who received DPd and were P-refractory, 2 (9%) were refractory to daratumumab. None of the patients, who received DRd and DVd and were not refractory to R and V respectively, were refractory to daratumumab. Among DRd patients refractory to R, 2 (8%) were daratumumab-refractory. Among patients who received DVd and who were refractory to V, 4 (23%)
were refractory to daratumumab.
| Survival analyses
The estimated median PFS for the entire cohort was 5.5 months (95% Table 2 and the survival curves for PFS are shown in Figure 2 . The curves for TTNT in these subgroups are given in the Supporting Information Appendix. The median PFS and TTNT were worse in those with high risk cytogenetics, those with pentarefractory and quadruple refractory disease, and those who were refractory to one or more agent used in the DCT.
The median PFS in the DPd group for patients who were Prefractory (n 5 22, 42%) and not P-refractory (n 5 30, 58%) was 2.7 (95% CI, 2.2-NR) and 5.5 (95% CI, 4.1-NR) months, respectively (P 5 .50) and median TTNT was 4.2 (95% CI, 2.6-NR) and 6.0 (95% CI, 4.4-NR) months, respectively (P 5 .22). In the DRd group, the median PFS was 6.0 (95% CI, 3.1-NR) months and NR (95% CI, NR-NR), respectively for the R-refractory (n 5 25, 73%) and not-R-refractory patients (n 5 9, 27%) (P 5 .04) and the median TTNT was 5.9 (95% CI,
3.2-NR) and NR (95% CI, 3.8-NR) months, respectively (P 5 .11). Within
the DVd group, the median PFS for the V-refractory (n 5 17, 74%) and not-V-refractory (n 5 6, 26%) patients were 3.8 (95% CI, 2.0-NR) months and NR (95% CI, NR-NR) respectively (P 5 .25). The median Quadruple refractory, n (%)
26 (21) 11 (21) 7 (21) 4 (17) 4 (23) .97
Penta refractory, n (%) ¶ 8 (6) 2 (4) 2 (6) 2 (8.7) 2 (12) .65
Refractory to 1 agents used in combination, n (%)
79 (63) 28 (54) 25 (73) 17 (74) 9 (53) .15
Refractory to immediate prior therapy, n (%)
116 (92) 48 (92) 32 (94) 19 (83) 17 (100) .21
Prior autologous SCT, n (%) 98 (78) 39 (75) 30 (88) 17 (74) 12 (71) .38
Prior allogeneic SCT, n (%) 5 (4) 2 (4) 0 (0) 1 (4) 2 (12) .25
Ranges and percentages have been rounded off to nearest whole number when possible; *P-value for Kruskal Wallis test for continuous variables and 
| Adverse events during therapy
Hematological adverse events were seen in 81.7% of all patients.
Grade 3 anemia, neutropenia or thrombocytopenia occurred in 13.5%, 32.5%, and 19.0% patients, respectively. Other common sideeffects were infections (37.3%), fatigue (31.6%), infusion reactions (17.3%), peripheral neuropathy (10.3%) and diarrhea (10.3%). Of the 17 patients who had been previously exposed to daratumumab, 6 had documented infusion reaction with single-agent daratumumab. So, together with 21 patients who had an infusion reaction with DCT, a total of 27 out of 119 (22.7%) patients for whom data was available, sustained a reaction to daratumumab. One patient developed pulmonary edema following daratumumab infusion and required noninvasive mechanical ventilation. Full list of adverse events during treatment is given in Supporting Information Appendix. Daratumumab dose was interrupted in 9 patients due to infection (n 5 4), thrombocytopenia (n 5 1), dyspnea (n 5 1), diarrhea with dehydration (n 5 1), fatigue and nausea (n 5 1) and for prophylactic nailing of a femoral lesion (n 5 1).
| D I SCUSSION
Our study involves a heavily pretreated MM patient-population as evidenced by a median of 4 prior lines of therapy and a median duration of 4.3 years between the diagnosis of MM and initiation of DCT. DCTs were initiated subsequent to the availability of daratumumab in the US, following its approval as monotherapy. We observed a median PFS and TTNT of 5.5 and 5.9 months, respectively, and 92% patients were alive at a median follow-up of 5.5 months following initiation of DCT.
Unfortunately, PFS and TTNT were shorter in patients who had high risk cytogenetics, those who had received >2 prior lines of therapy, those who were refractory to 1 agents used in the DCT and those who had quadruple refractory or penta-refractory MM.
Initial results of the CASTOR and POLLUX studies showed an ORR of 83% and 93% at median follow-up periods of 7.4 and 13.5 months, respectively for the two trials. 15, 16 The estimated 12-month PFS was 61% and 83% respectively in CASTOR and POLLUX studies compared to 30% in our series. The remarkably worse ORR and PFS observed in our study, compared to CASTOR and POLLUX, can be accounted for by certain cardinal dissimilarities in the patient-populations. The POL-LUX trial excluded patients who were refractory to lenalidomide and the CASTOR trial excluded patients who were refractory to bortezomib.
For both studies, exposure to an anti-CD38 monoclonal antibody was an exclusion criterion, compared to 17 patients who were exposed to daratumumab and 1 patient who was exposed to isatuximab in our cohort. Based on their prior treatment and drug refractoriness, at least 96 (76%) and 102 (81%) patients in our cohort would have been ineligible for CASTOR and POLLUX, respectively. In CASTOR, approximately 23% patients had received >2 prior lines of therapy, the median prior therapies being 2 (range, 1-9). The median for prior therapies in POLLUX was only 1 (range, 1-11). Only about 30% patients were refractory to last line of therapy in both studies. In contrast, our patients had a median of 4 prior therapies, with 76% patients having received >2 prior therapies, and 92% being refractory to the last line of .45
Percentages have been rounded off to the closest whole number. CI: confidence interval; NR: not reached.
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therapy. The median time from diagnosis to initiation of daratumumab was 3.9 years (range, 0.7-21) in CASTOR and 3.5 years (range, 0. in POLLUX, compared to over 4 years (range, 0.4-13.0) in our study. In the EQUULEUS trial, RRMM patients receiving 2 prior therapies who were refractory to last line of treatment received DPd. The ORR of 60% and 12-month PFS of 42% seen among these patients with a median of 4 (range, 1-13) prior therapies and 5.1 years from diagnosis are lower when compared to CASTOR and POLLUX, suggesting that more heavily pretreated the study population, the worse the outcomes. 20 Our cohort represents a patient population closer to real world clinical practice,
where DCTs were used after exhaustion of multiple available therapies at the time of its approval. Our findings are comparable to those of a retrospective study of patients treated with DPd wherein 78% patients were refractory to last line of therapy. 21 We noted a respectable ORR of 47% and CBR of 66%, the ORR being comparable to 41% seen in the aforementioned study. 21 In the patients refractory to D and/or P who received DPd, we observed an ORR of 43%, which is similar to 41%
ORR observed in another retrospective review of patients who received DPd. 22 In patients who were not refractory to P and unexposed to D, we observed an ORR of 54%, and an estimated 12-month PFS of 31%, somewhat similar to the outcomes in EQUULEUS trial. 20 The vast majority of our patients who attained a response did not progress or die by the cut-off date. Estimated OS was over 92%, and 70% at 6 months and 1 year respectively from initiation of DCT. These results are promising, considering the heavily pretreated nature of our population.
We observed worse ORR and CBR, and longer time to best response in patients with high risk cytogenetics, but no such difference was noted when patients were stratified on the basis of prior therapy.
Patients with high risk cytogenetics, those who received more than 2 prior lines of therapies, those who were refractory to 1 agent used in the DCT or those with quadruple/penta-refractory MM had a significantly worse PFS and TTNT. Our observations suggest that using DCTs early in the course of the disease, before a patient becomes multi-refractory may lead to superior outcomes. This observation should be interpreted together with the fact that DCTs in CASTOR and POLLUX trials have resulted in faster and higher rates of minimal residual disease (MRD) negative remissions (10% and 32%, respectively) as compared to the doublets used in the control arms, which in turn translated into prolonged PFS. 30, 31 As a result, DCTs are being recommended as salvage therapy for patients at their first relapse by our group (www.msmart.org) as well as other groups. 32, 33 Our study supports this approach as we found worse outcomes for patients who were refractory to multiple previously used drugs.
The side-effects were predominantly hematological, and primarily related to the back-bone regimens used with daratumumab. Infusion reactions were noted in a smaller proportion compared to 45%-50% reported in clinical trials. 15, 16, 20, 21 None of the patients excluded from the analysis for receiving <1 cycle of DCT had serious infusion reactions. The lower observed rate of infusion reactions in our study may partly be due to minor reactions being under-reported in the electronic medical records.
The principal strength of this study is its large cohort that received DCTs within the first year after its approval as monotherapy. Furthermore, by including a heavily pretreated patient population, the study cohort represents a patient population close to the current "real world"
practice outside the clinical trials. The major limitation of our study is its retrospective nature, which among other inherent drawbacks associated with a retrospective analysis, may have limited our ability to accurately collect data pertaining to the toxicities. 34 A bone marrow examination to document complete remission was not done routinely in clinical practice. Besides, our follow-up period was short, thereby resulting in our inability to make a robust assessment of OS.
Despite the short follow-up, our study shows that DCT provides 
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